Search
Dronabinol
go.drugbank.com/drugs/DB00470ApprovedIllicitInvestigationalDue to its evidence as an appetite stimulant and an anti-nauseant, Dronabinol is approved for use in anorexia associated with weight loss in patients with AIDS and for the treatment of nausea and vomiting … CB2 receptors are mainly located in the peripheral nervous system and can be found on lymphoid tissue where they are involved in regulation of immune function [A32676].
Vibegron
go.drugbank.com/drugs/DB14895ApprovedInvestigationalOn December 23, 2020, vibegron was approved for the same indication in adults. It is available as oral tablets under the market name GEMTESA. … [L28305] Vibegron was first approved in Japan in September 2018 for the treatment of overactive bladder,[A226050] a condition associated with distressing symptoms of urge urinary incontinence, urgency,
Ephedrine
go.drugbank.com/drugs/DB01364ApprovedInvestigationalEphedrine was first described in western literature in 1888, as a naturally occurring component of the ephedra plant, along with [pseudoephedrine]. … [A193701,A193704,L12975] Ephedrine was granted a type 7 FDA Approval on 29 April 2016.[L12975]
Mixtures: COPHADYL-E COUGH LINCTUSProducts: Ephedrinhydrochlorid Aguettant 3 mg/ml Injektionslösung in FertigspritzeEslicarbazepine acetate
go.drugbank.com/drugs/DB09119ApprovedInvestigationalEslicarbazepine acetate (ESL) is an anticonvulsant medication approved for use in Europe, the United States and Canada as an adjunctive therapy for partial-onset seizures that are not adequately controlled … Eslicarbazepine acetate is marketed as Aptiom in North America and Zebinix or Exalief in Europe. It is available in 200, 400, 600, or 800mg tablets that are taken once daily, with or without food.
Betibeglogene autotemcel
go.drugbank.com/drugs/DB16900ApprovedInvestigationalThe use of betibeglogene autotemcel is more effective in patients with β-thalassemia with residual β-globin synthesis (non-β<sup>0</sup>/β<sup>0</sup> genotype) compared to those with no detectable β-globin … [A251770,A251785] Betibeglogene autotemcel was approved by the FDA in August 2022 and is the first ex-vivo lentiviral vector gene therapy available in the U.S. for the treatment of people with β-thalassemia
Categories: Complex MixturesDexfenfluramine
go.drugbank.com/drugs/DB01191ApprovedIllicitWithdrawnFor a fairly limited time during the middle of the nineties, the US FDA had approved it for use in managing weight loss.
Synonyms: d-N-ethyl-α-methyl-m-trifluoromethylphenethylamine, (S)-N-ethyl-1-[3-(trifluoromethyl)phenyl]propan-2-amineHistrelin
go.drugbank.com/drugs/DB06788ApprovedInvestigationalWithdrawnAs the product Supprelin LA, histrelin is indicated for the treatment of CPP in children (approved by the FDA in May 2007).[L41700] … [L41715] Vantas was later discontinued by Endo Pharmaceuticals Inc. on September 21, 2021.
Synonyms: 5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-1-benzyl-D-histidyl-L-leucyl-L-arginyl-N-ethyl-L-prolinamide, 5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-Nτ-benzyl-D-histidyl-L-leucyl-L-arginyl-N-ethyl-L-prolinamideLebrikizumab
go.drugbank.com/drugs/DB11914ApprovedInvestigational[L51374] It binds to a different epitope compared [tralokinumab]. … [A262874,A262879] On November 17, 2023, lebrikizumab was approved by the EMA under the brand name EBGLYSS for the treatment of moderate-to-severe atopic dermatitis in adult and adolescent patients 12
Gatifloxacin
go.drugbank.com/drugs/DB01044ApprovedInvestigationalWithdrawnpatients taking gatifloxacin compared to those on macrolide antibiotics. … It was first introduced by Bristol-Myers Squibb in 1999 under the brand name Tequin® for the treatment of respiratory tract infections.
Categories: Compounds used in a research, industrial, or household settingGadoquatrane
go.drugbank.com/drugs/DB33282Approvedin the central nervous system and in the body. … [L63930] Bayer announced FDA approval of gadoquatrane on June 15, 2026, for use with MRI in adult and pediatric patients, including term neonates, to detect and visualize lesions with abnormal vascularity